Healthful Transformations

08/22/2025

08/22/2025

08/19/2025

🚨 CRITICAL STUDY ALERT: A rigorous analysis with over 380 references reveals a shocking link between mRNA vaccines and SARS-CoV-2, driving a global surge in excess deaths and chronic illness.

The "Synergistic Damage Hypothesis" suggests mRNA shots may prime the body for prolonged harm, worsened by COVID-19 infections.

These vaccines deliver spike proteins, lipid nanoparticles, and residual DNA, spreading to critical organs like the heart, brain, ovaries, and placenta, potentially disrupting immune function.

Key findings include:

• Spike proteins, lipid nanoparticles, and DNA contaminants trigger immune dysregulation.

• These components distribute widely, affecting heart, brain, reproductive systems, and more.

• Spike proteins may persist for months or years, possibly due to genomic integration.

• Additional mRNA doses deepen immune dysregulation, increasing vulnerability.

• Vaccination and infection combine to amplify damage to organs and systems.

Global data indicates mRNA vaccines lose efficacy after about six months, with higher doses tied to increased COVID-19 infections, hospitalizations, and deaths, especially in populations with over 75% vaccination rates.

Countries with widespread mRNA use show persistent excess deaths, even after less severe variants like Omicron, often among fully vaccinated or boosted individuals.

If correct, this hypothesis implies millions remain at risk of severe illness or death with each reinfection, fueled by the interplay of mRNA vaccines and a lab-engineered virus.

This study exposes a health crisis of unprecedented magnitude, demanding urgent scrutiny of mRNA vaccine safety and accountability for those who championed their rollout.

🔗 Read the study: https://www.preprints.org/manuscript/202508.1082/v1

🔗 Read the full report: https://www.thefocalpoints.com/p/breaking-manuscript-mrna-vaccines

08/19/2025

🚨 CDC SUED IN FEDERAL COURT FOR FAILING TO STUDY SAFETY OF 72-DOSE CHILDHOOD VACCINE SCHEDULE

A groundbreaking lawsuit has been filed against the Centers for Disease Control and Prevention (CDC), accusing it of neglecting to study the cumulative effects of the 72-dose childhood vaccine schedule.

Drs. Paul Thomas and Kenneth P. Stoller, joined by Stand for Health Freedom, are demanding answers in a case that could reshape vaccine safety discussions.

The childhood vaccine schedule recommends up to 72 doses by age 18 to protect against 16 diseases—a significant jump from 24 doses in 1983.

According to the lawsuit, filed by attorney Rick Jaffe in the U.S. District Court for the District of Columbia, the CDC has not conducted comprehensive studies on how these vaccines interact or their combined impact, including ingredients like aluminum and potential long-term health effects.

Without this research, questions about the schedule’s safety remain unanswered.

The lawsuit cites the National Childhood Vaccine Injury Act of 1986, enacted to ensure vaccine safety while protecting manufacturers after lawsuits over the diphtheria-tetanus-pertussis (DTP) vaccine in the 1980s.

The law mandated that the Department of Health and Human Services create a task force and submit biennial safety reports to Congress.

However, the task force was disbanded in 1998, and no reports were EVER filed.

Children’s Health Defense (CHD), which supports the lawsuit, emphasizes the need for accountability. CEO Mary Holland stated, “The CDC’s failure to study the full vaccine schedule undermines public trust.”

The suit demands the CDC produce evidence of cumulative safety studies or admit it lacks them.

This legal action follows a June 2025 announcement by the CDC’s Advisory Committee on Immunization Practices, led by Dr. Martin Kulldorff, to begin studying these effects—likely spurred by this case.

This matters because the Vaccine Adverse Event Reporting System (VAERS) has recorded over 2.5 million adverse event reports, though a 2011 Harvard study estimates less than 1% of injuries are reported.

With chronic conditions like autism (1 in 36 children in 2020) and autoimmune disorders rising, parents are concerned. A John Zogby Strategies poll found 60% of parents with young children support reviewing the vaccine schedule.

This lawsuit is a call for transparency in public health.

https://www.facebook.com/share/1ESzVH8WAR/?mibextid=WC7FNe

🚨 CDC SUED IN FEDERAL COURT FOR FAILING TO STUDY SAFETY OF 72-DOSE CHILDHOOD VACCINE SCHEDULE

A groundbreaking lawsuit has been filed against the Centers for Disease Control and Prevention (CDC), accusing it of neglecting to study the cumulative effects of the 72-dose childhood vaccine schedule.

Drs. Paul Thomas and Kenneth P. Stoller, joined by Stand for Health Freedom, are demanding answers in a case that could reshape vaccine safety discussions.

The childhood vaccine schedule recommends up to 72 doses by age 18 to protect against 16 diseases—a significant jump from 24 doses in 1983.

According to the lawsuit, filed by attorney Rick Jaffe in the U.S. District Court for the District of Columbia, the CDC has not conducted comprehensive studies on how these vaccines interact or their combined impact, including ingredients like aluminum and potential long-term health effects.

Without this research, questions about the schedule’s safety remain unanswered.

The lawsuit cites the National Childhood Vaccine Injury Act of 1986, enacted to ensure vaccine safety while protecting manufacturers after lawsuits over the diphtheria-tetanus-pertussis (DTP) vaccine in the 1980s.

The law mandated that the Department of Health and Human Services create a task force and submit biennial safety reports to Congress.

However, the task force was disbanded in 1998, and no reports were EVER filed.

Children’s Health Defense (CHD), which supports the lawsuit, emphasizes the need for accountability. CEO Mary Holland stated, “The CDC’s failure to study the full vaccine schedule undermines public trust.”

The suit demands the CDC produce evidence of cumulative safety studies or admit it lacks them.

This legal action follows a June 2025 announcement by the CDC’s Advisory Committee on Immunization Practices, led by Dr. Martin Kulldorff, to begin studying these effects—likely spurred by this case.

This matters because the Vaccine Adverse Event Reporting System (VAERS) has recorded over 2.5 million adverse event reports, though a 2011 Harvard study estimates less than 1% of injuries are reported.

With chronic conditions like autism (1 in 36 children in 2020) and autoimmune disorders rising, parents are concerned. A John Zogby Strategies poll found 60% of parents with young children support reviewing the vaccine schedule.

This lawsuit is a call for transparency in public health.

08/19/2025

Texas Attorney General Ken Paxton is suing Eli Lilly for allegedly "bribing" doctors to prescribe the company's most profitable drugs, including GLP-1 weight-loss medications Mounjaro and Zepbound.

08/18/2025

I'm beyond amazed how defensive people get over drugs like Ozempic. Remember that this is an ALL NATURAL HEALTH GROUP. Suggesting, defending, recommending or promoting pharma drugs is against our group rules. Go to a medical group if pharma is your thing.

Meanwhile, for those interested:

OZEMPIC LAWSUIT

There are ongoing lawsuits against Ozempic in 2025, primarily targeting its manufacturer, Novo Nordisk, and in some cases, Eli Lilly, the maker of related drugs like Mounjaro. These lawsuits have been consolidated into a federal Multidistrict Litigation (MDL No. 3094) in the Eastern District of Pennsylvania, presided over by Judge Karen S. Marston. As of August 1, 2025, the MDL includes 2,190 pending cases, with steady growth reported throughout the year (e.g., 1,882 cases in June 2025, 1,809 in May 2025). Additionally, separate state-level lawsuits and a proposed multicounty litigation (MCL) in New Jersey are addressing specific claims, particularly vision loss.Key Allegations:

• Primary Injuries: The lawsuits focus on severe side effects, including:

◦ Gastroparesis (stomach paralysis): A condition causing delayed gastric emptying, leading to chronic nausea, vomiting, abdominal pain, and, in severe cases, hospitalization or tooth loss due to gastric acid exposure.

◦ Intestinal Blockages (Ileus): Bowel obstructions causing significant digestive complications.

◦ Vision Loss (NAION): Non-arteritic anterior ischemic optic neuropathy, a serious eye condition linked to sudden, potentially permanent blindness.

◦ Blood Clots: Deep vein thrombosis (DVT) and pulmonary embolism (PE), with a 2022 study noting a 266% increased risk of DVT in Ozempic users.

◦ Gallbladder Issues: Gallstones and inflammation (cholecystitis), sometimes requiring surgical intervention.

◦ Pancreatitis: Reports of acute pancreatitis, with U.K. regulators investigating genetic predispositions.

◦ Hair Loss: A recent study (August 2025) found a 52% higher risk of hair loss in Ozempic users, with women facing double the risk compared to non-users.

• Legal Claims: Plaintiffs allege that Novo Nordisk:

◦ Failed to adequately warn patients and doctors about these risks.

◦ Misrepresented the drug’s safety through misleading marketing.

◦ Negligently designed the drug or concealed known risks.

◦ Prioritized profits over patient safety by ignoring adverse event reports.

Litigation Details:

• MDL Scope: The MDL covers Ozempic, Wegovy, Rybelsus (all semaglutide-based), as well as Trulicity and Mounjaro (other GLP-1 receptor agonists). It centralizes federal cases to streamline discovery and ensure consistent rulings, but each case remains individual, unlike a class action.

• Vision Loss Claims: Over 60 vision-related lawsuits, particularly for NAION, are pending, with a potential separate MDL or MCL in New Jersey proposed to handle these distinct claims. A 2025 study linked semaglutide to a two- to fourfold higher risk of NAION, prompting calls for updated warning labels.

• Current Stage: The litigation is in the discovery phase, with fact discovery deadlines set for July 2025 and expert reports due by mid-August 2025. Bellwether trials (test cases) are expected in late 2025 or 2026, which could influence settlement discussions.

• Settlement Estimates: No settlements have been reached yet, but legal experts estimate potential payouts of $400,000–$700,000 for severe gastroparesis cases and up to $1 million for NAION cases involving permanent vision loss. Compensation may cover medical expenses, lost wages, pain and suffering, and, in some cases, punitive damages.

Other Developments:

• Regulatory Updates: In 2024, the FDA updated Ozempic’s label to include delayed gastric emptying as an adverse event, but plaintiffs argue it still lacks explicit warnings for gastroparesis or NAION. The European Medicines Agency (EMA) has recommended adding NAION as a “very rare” side effect.

• Counterfeit Issues: Novo Nordisk has filed 132 lawsuits across 40 states against companies selling compounded semaglutide, citing safety risks and trademark violations. These actions are separate from injury claims but highlight concerns about non-FDA-approved alternatives.

• Investor Lawsuits: In August 2025, investors filed class actions against Novo Nordisk, alleging misleading revenue projections, adding financial pressure on the company.

Eligibility to File: You may qualify to join the lawsuits if you:

• Used Ozempic, Wegovy, Rybelsus, Trulicity, or Mounjaro.

• Developed gastroparesis, ileus, NAION, blood clots, or severe gallbladder issues requiring medical intervention.

• Have medical records documenting your diagnosis and treatment.

• Experienced symptoms like chronic vomiting, severe abdominal pain, or sudden vision loss.

Next Steps:

• Document Everything: Gather medical records, prescription details, and a symptom log.

• Consult an Attorney: Firms specializing in pharmaceutical litigation, like those referenced in MDL 3094, offer free case evaluations.

• Act Promptly: Statutes of limitations (typically 1–3 years from injury or discovery) vary by state, so timely action is critical.

Sentiment on X: Recent posts on X reflect growing public concern, with claims of a $2 billion lawsuit tied to vision loss (NAION) in over 1,800 users and gastrointestinal issues.